INTRODUCTION
Although acne is one of the most common skin
disorders, its pathogenesis is not clearly understood.
Propionibacterium acnes (P. acnes) is a commensal
organism that plays an active role in acne vulgaris. P. acnes
thrives in the presence of excess sebum and has been shown
to mediate inflammatory processes at the site of the sebaceous
follicle, contributing to the formation of free radical species
and generating pro-inflammatory cytokines.1 Coupled with
faulty keratinization, excess sebum production and P. acnes
colonization contribute to the formation of microcomedones,
ultimately leading to development of the comedones, papules,
pustules and cysts characteristic of acne.
While the appearance of active acne vulgaris can have a significant
impact on a person’s appearance and can be associated
with potential physical discomfort, the scarring following
acne is the most devastating sequelum to the patient. A better
understanding of the pathophysiology of acne and associated
scarring has been gained with the most recent in vivo research
by Kang et al.2 They reported a marked increase in inflammatory
cytokine gene transcripts in active acne lesions, including
TNF-α and IL-1b. Importantly, these pro-inflammatory cytokines
amplify NF-kB signaling pathways that originally led to their
production while also stimulating nearby cells, according to the
authors. This investigation also identified significant increases
in IL-8 and IL-10. In addition to NF-kB, Activator Protein-1 (AP)-1
is also elevated in acne lesions, leading to elevated matrix metalloproteinases,
which degrade collagen—up to 2.5-fold compared
to normal skin. Furthermore, the authors note that the
inflammatory process is localized to the pilosebaceous unit.2
The most common sequelum of inflammatory acne is scarring,
which is devastating to patients. The best way to prevent scarring
is, of course, to prevent and treat inflammatory lesions
as early as possible. Also, any agent blocking (AP)-1, which increases matrix metalloproteinases that cause scarring via collagen
degradation, will be useful in scar prevention.
Topical treatment options for acne include retinoids, antimicrobials,
such as erythromycin and clindamycin, and benzoyl
peroxide (BPO). Different combination formulations of retinoids,
antibiotics and BPO are also available. Topical retinoids
primarily act to normalize hyperkeratinization and have been
suggested to confer mild anti-inflammatory effects. Topical
antimicrobials and benzoyl peroxide target P. acnes, diminishing
colonization. Topical antimicrobials may also confer antiinflammatory
effects.
Despite the well-known and recently re-affirmed role of inflammation
in acne, no primarily anti-inflammatory topical therapy
has been available for acne. Anti-inflammatory topical dapsone
5% gel (Aczone Gel 5%, Allergan, Irvine, CA) is now available
for topical treatment of acne.
Mechanisms of Action
Although dapsone has proven to be a very powerful treatment
in several neutrophilic dermatoses (such as dermatitis herpetiformis)
through its anti-inflammatory effects, the mechanism of
action of this effect is not well understood. There are several in
vitro studies that show the anti-inflammatory effect of dapsone.
The successful use of oral dapsone in several sub-epidermal
blistering diseases is associated with anti-inflammatory effects
by the suppression of neutrophil and eosinophil functions. This
effect was demonstrated through dapsone’s inhibition of IL-8
release in cultured human keratinocytes.3
It also has been shown that dapsone suppressed leukocyte integrin
function, thus inhibiting migration of neutrophils to extravascular
sites.4 Further, in vitro studies by Debol et al. show that
dapsone inhibits chemoattractant-induced G-protein activation
and suppresses the subsequent signal transduction cascade.5